Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Microsoft, Amazon, Ulta Beauty, Okta, Biogen, Meta & more

Wall Street research calls were broadly constructive, with multiple upgrades and bullish initiations across tech, healthcare, industrials, and materials. Notable changes included Jefferies raising Tesla's price target to $350 from $300 while keeping Hold, Bank of America lifting Amazon's target to $298 from $275, and several upgrades to Buy/Overweight for Plexus, Ulta, Ecolab, Okta, Biogen, Williams Companies, and Air Products. The most negative calls were Mizuho's downgrades of Skyworks and Qorvo to Underperform and Wells Fargo's cut on NXP to Equal Weight, reflecting softer handset and auto demand concerns.

Analysis

The clearest factor today is the market rewarding companies with either pricing power or visible AI/industrial capex exposure, while punishing names where end-demand or handset mix looks structurally less favorable. That creates a cleaner relative-value setup inside semis: downstream analog/RF names with handset dependence look vulnerable to earnings revision cuts, while the AI infrastructure stack still has room to run because hyperscale spending is becoming less discretionary and more re-baselined into operating budgets. The key second-order effect is that every dollar redirected into AI training/inference is a dollar not flowing into legacy mobile silicon, so the dispersion within semis should widen further over the next 1-2 quarters.

A more interesting read-through is that several upgrades are really balance-sheet or capital-allocation stories masquerading as growth calls. Midstream, industrials, and specialty chemicals benefit when investors gain confidence that management will actually convert backlog/capex into free cash flow rather than into perpetual reinvestment; that supports multiple expansion even without major estimate changes. In contrast, Tesla remains the most fragile setup in the group: the market will increasingly treat future upside as event-driven rather than fundamental, and absent a credible monetization milestone, capex intensity can become a drag on both earnings power and optionality.

On the thematic side, rare earths and uranium are now being bid as strategic supply-chain assets, not pure commodity plays. That is constructive for names tied to constrained western supply, but it also means valuation can outrun fundamentals quickly if capital formation accelerates or if policy headlines fade. Biotech and software remain cleaner catalyst setups because they have identifiable data/earnings windows, whereas the delivery/autonomy and quantum names are more likely to trade on narrative momentum than near-term revenue.

Key Decisions for Investors

• Favor a pair trade: long NVDA / short SWKS or QRVO into earnings season. The asymmetry is better over the next 1-3 months because AI demand is still underappreciated while handset exposure is a slower-moving downgrade cycle.
• Add to MSFT on any post-earnings weakness versus a basket of AI beneficiaries. Use a 4-8 week horizon; the market is likely to pay for Azure and AI execution more than for headline beat/miss.
• Long OKTA versus a broad software basket for 1-2 quarters. Identity is becoming a board-level spend priority, so the setup has better rev durability than most mid-cap SaaS names; downside is mainly if enterprise security budgets pause.
• Tactically buy BIIB on pullbacks over the next 6-12 months. This is a catalyst-dense rerating story with multiple shots on goal, and the risk/reward improves if the market continues to pay for pipeline diversification.
• Use TSLA only as a short-dated event trade, not a core long. If there is no credible robotaxi or monetization update, upside should be capped; consider selling upside calls against stock or expressing bearishness via put spreads.